A Study to Evaluate the Effect of a Single 250 mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856).

Trial Profile

A Study to Evaluate the Effect of a Single 250 mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856).

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2010

At a glance

  • Drugs Dolutegravir; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; HIV-1 infections; Intra-abdominal infections; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Jan 2010 Actual patient number (42) added as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top